About The Study: Valacyclovir, an antiviral medication, was not efficacious with cognitive worsening for the primary outcome and it is not recommended to treat individuals with early symptomatic Alzheimer disease and herpes simplex virus seropositivity.
Corresponding Author: To contact the corresponding author, D. P. Devanand, MD, email dpd3@cumc.columbia.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.21738)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.21738?guestAccessKey=2b0c16c4-ad92-4700-ad9b-ae3dea904157&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121725
Journal
JAMA